Advertisement


Timothy J. Whelan, MD: When Can Radiotherapy Be Avoided After Breast-Conserving Surgery?

2022 ASCO Annual Meeting

Advertisement

Timothy J. Whelan, MD, of McMaster University and Hamilton Health Sciences, discusses findings from the LUMINA study, which found that women aged 55 or older who had grade 1–2 T1N0 luminal A breast cancer following breast-conserving surgery and were treated with endocrine therapy alone had very low rates of local tumor recurrence at 5 years. These patients, the research suggests, may be able to forgo radiotherapy (Abstract LBA501).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Women with breast cancer, early stage breast cancer, are primarily treated with lumpectomy, often endocrine therapy and radiation. And for many years now we've realized that the risk of local recurrence after lumpectomy has been steadily decreasing, and this has been attributed to smaller screen detected cancers, better surgical therapies and better systemic therapy. And radiation itself is associated with significant side effects, both early, such as fatigue and skin irritation, and late side effects such as breast distortion, which can affect cosmesis and quality of life. And rare life threatening side effects such as cardiac disease and second cancers. The question is arisen, can we avoid radiotherapy in women who are already going to have lumpectomy and endocrine therapy? We've done a number of studies which have evaluated clinical pathological factors alone, but haven't been able to identify a very low risk group of patients after lumpectomy and endocrine therapy alone. But over the last two decades, we realized a better understanding of the molecular biology of breast cancer and have identified four major intrinsic subtypes of breast cancer. Luminal A being the most common subtype and also the lowest risk subtype. The objective of our study was to determine women with clinical pathological factors, low risk and the Luminal A subtype who were treated with lumpectomy and endocrine therapy alone. Could they avoid radiotherapy? The Luminal was a prospective cohort study where we followed 500 women who had low clinical risk factors and Luminal A subtype determined by ER, PR, HER2 and a low Ki-67, less than 13.25%, which was measured centrally in three labs using the international working group methods. And we found over five years that women had a very low rate of local recurrence, only 2.3% with the upper border of the 90% confidence interval being 3.8%, which was well below the 5% limit that we had set for ourselves. We believe that this rate is very low and constitutes that we could omit radiotherapy in this low risk subtype. Should point out that the risk of contralateral breast cancer in this group of women was only 1.8%. Very similar to the risk of local recurrence and the risk of any recurrence was only 2.7%. Again, a low risk group of patients. Based on these results in women who meet the clinical criteria for the study, and I'll mention again, they were women less than or equal to 50 or greater than or equal to 55 years of age who had a T1 N0 cancer, grades 1 and 2, and the luminal A subtype as we determined who were treated with endocrine therapy, they can avoid radiotherapy. Now, although Luminal A is a common subtype, we estimate that this group of women probably constitutes about 10 to 15% of all women with breast cancer. Given that the risk of invasive breast cancer is about 300,000 annually per year in North America, we estimate that this would relate to about 30 to 40,000 women per year.

Related Videos

Neuroendocrine Tumors

Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel

Mairéad G. McNamara, PhD, MBBCh, of The Christie NHS Foundation Trust, discusses phase II findings of the NET-02 trial, which explored an unmet need in the second-line treatment of patients with progressive, poorly differentiated extrapulmonary neuroendocrine carcinoma. In the trial, the combination of liposomal irinotecan, fluorouracil, and folinic acid, but not docetaxel, met the primary endpoint of 6-month progression-free survival rate (Abstract 4005).

Kidney Cancer
Immunotherapy

Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: New Data on Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, discuss phase III findings from the KEYNOTE-426 trial, which appear to support the long-term benefit of pembrolizumab plus axitinib for first-line treatment of patients with advanced clear cell renal cell carcinoma (Abstract 4513).

Lung Cancer
Genomics/Genetics

Gilberto de Lima Lopes, Jr, MD, MBA, and Matthew Krebs, PhD, on NSCLC: Updated Results With Amivantamab-vmjw

Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, and Matthew Krebs, PhD, of The University of Manchester and The Christie NHS Foundation Trust, discuss results from the CHRYSALIS study. The trial showed that the bispecific antibody amivantamab-vmjw demonstrated antitumor activity, even after prior treatment, in patients with non–small cell lung cancer that exhibits the MET exon 14 skipping mutation (Abstract 9008).

Breast Cancer

Robert Hugh Jones, MD, PhD, on Breast Cancer: Updated Overall Survival Data on Fulvestrant Plus Capivasertib

Robert Hugh Jones, MD, PhD, of Cardiff University and Velindre Hospital, discusses results from an updated analysis of the FAKTION trial, which showed improved overall survival with fulvestrant plus capivasertib in women with metastatic estrogen receptor–positive breast cancer whose disease had relapsed or progressed on an aromatase inhibitor. The benefit may be predominantly in patients with PIK3CA/AKT1/PTEN pathway–altered tumors, a topic researchers continue to study in the phase III CAPItello-291 trial (Abstract 1005).

 

Breast Cancer
Immunotherapy

Lisa A. Carey, MD, and Shanu Modi, MD, on Breast Cancer: Is T-DXd a Potential New Standard of Care for HER2-Low Disease?

Lisa A. Carey, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discuss the phase III findings from the DESTINY-Breast04 trial, which compared fam-trastuzumab deruxtecan-nxki (T-DXd) vs treatment of physician’s choice (TPC) in patients with HER2-low unresectable and/or metastatic breast cancer. T-DXd is the first HER2-targeted therapy to demonstrate clinically meaningful improvement in progression-free and overall survival compared with TPC in this patient population, regardless of hormone receptor or immunohistochemistry status or prior use of CDK4/6 inhibitors (Abstract LBA3).

Advertisement

Advertisement




Advertisement